» Articles » PMID: 31671105

Comparison of HIV-1 Vif and Vpu Accessory Proteins for Delivery of Polyepitope Constructs Harboring Nef, Gp160 and P24 Using Various Cell Penetrating Peptides

Overview
Journal PLoS One
Date 2019 Nov 1
PMID 31671105
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

To develop an effective therapeutic vaccine against HIV-1, prediction of the most conserved epitopes derived from major proteins using bioinformatics tools is an alternative achievement. The epitope-driven vaccines against variable pathogens represented successful results. Hence, to overcome this hyper-variable virus, we designed the highly conserved and immunodominant peptide epitopes. Two servers were used to predict peptide-MHC-I binding affinity including NetMHCpan4.0 and Syfpeithi servers. The NetMHCIIpan3.2 server was utilized for MHC-II binding affinity. Then, we determined immunogenicity scores and allergenicity by the IEDB immunogenicity predictor and Algpred, respectively. Next, for estimation of toxicity and population coverage, ToxinPred server and IEDB population coverage tool were applied. After that, the MHC-peptide binding was investigated by GalexyPepDock peptide-protein flexible docking server. Finally, two different DNA and peptide constructs containing Nef-Vif-Gp160-P24 and Nef-Vpu-Gp160-P24 were prepared and complexed with four various cell penetrating peptides (CPPs) for delivery into mammalian cells (MPG and HR9 CPPs for DNA delivery, and CyLoP-1 and LDP-NLS CPPs for protein delivery). Our results indicated that the designed DNA and peptide constructs could form non-covalent stable nanoparticles at certain ratios as observed by scanning electron microscope (SEM) and Zetasizer. The flow cytometry results obtained from in vitro transfection of the nanoparticles into HEK-293T cell lines showed that the percentage of GFP expressing cells was about 38.38 ± 1.34%, 25.36% ± 0.30, 54.95% ± 0.84, and 25.11% ± 0.36 for MPG/pEGFP-nef-vif-gp160-p24, MPG/pEGFP-nef-vpu-gp160-p24, HR9/pEGFP-nef-vif-gp160-p24 and HR9/pEGFP-nef-vpu-gp160-p24, respectively. Thus, these data showed that the DNA construct harboring nef-vif-gp160-p24 multi-epitope gene had higher efficiency than the DNA construct harboring nef-vpu-gp160-p24 multi-epitope gene to penetrate into the cells. Moreover, delivery of the recombinant Nef-Vif-Gp160-P24 and Nef-Vpu-Gp160-P24 polyepitope peptides in HEK-293T cells was confirmed as a single band about 32 kDa using western blot analysis. Although, both DNA and peptide constructs could be successfully transported by a variety of CPPs into the cells, but the difference between them in transfection rate will influence the levels of immune responses for development of therapeutic vaccines.

Citing Articles

Novel SARS-COV2 poly epitope phage-based candidate vaccine and its immunogenicity.

Hasani S, Behdani M, Amirkhani Z, Rahimmanesh I, Esmaeilifallah M, Zaker E Res Pharm Sci. 2024; 19(5):573-590.

PMID: 39691297 PMC: 11648347. DOI: 10.4103/RPS.RPS_82_24.


The Role of Peptides in Combatting HIV Infection: Applications and Insights.

Helmy N, Parang K Molecules. 2024; 29(20).

PMID: 39459319 PMC: 11510642. DOI: 10.3390/molecules29204951.


Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection.

Habib A, Liang Y, Xu X, Zhu N, Xie J Int J Mol Sci. 2024; 25(4).

PMID: 38397105 PMC: 10889372. DOI: 10.3390/ijms25042432.


B1 protein: a novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs.

Kardani K, Bolhassani A, Agi E, Hashemi A Biotechnol Lett. 2020; 42(10):1847-1863.

PMID: 32449070 PMC: 7246087. DOI: 10.1007/s10529-020-02918-w.

References
1.
Krupka M, Zachova K, Cahlikova R, Vrbkova J, Novak Z, Sebela M . Endotoxin-minimized HIV-1 p24 fused to murine hsp70 activates dendritic cells, facilitates endocytosis and p24-specific Th1 response in mice. Immunol Lett. 2015; 166(1):36-44. DOI: 10.1016/j.imlet.2015.05.010. View

2.
Milani A, Bolhassani A, Shahbazi S, Motevalli F, Sadat S, Soleymani S . Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol Lett. 2017; 191:16-22. DOI: 10.1016/j.imlet.2017.09.005. View

3.
Tissot A, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V . Versatile virus-like particle carrier for epitope based vaccines. PLoS One. 2010; 5(3):e9809. PMC: 2843720. DOI: 10.1371/journal.pone.0009809. View

4.
Belnoue E, di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F . Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Mol Ther. 2016; 24(9):1675-85. PMC: 5113103. DOI: 10.1038/mt.2016.134. View

5.
Ponnappan N, Chugh A . Cell-penetrating and cargo-delivery ability of a spider toxin-derived peptide in mammalian cells. Eur J Pharm Biopharm. 2017; 114:145-153. DOI: 10.1016/j.ejpb.2017.01.012. View